DONATE

Pau Gorostiza

Group leader

New chemical lego blocks for health solutions

IBEC researchers develop new multi-responsive molecules able to self-assemble in water forming fiber-like structures. The so-called discotic molecules show responsiveness to temperature, light, pH, and ionic strength and they might show great potential for medical applications such as drug delivery systems, diagnosis or tissue engineering.

Edgar Fuentes is a PhD student in the Nanoscopy for Nanomedicine Group led by Lorenzo Albertazzi at the Institute for Bioengineering of Catalonia (IBEC). Within this group, Edgar and his colleagues focus on the synthesis of novel smart supramolecular materials for drug delivery.

Rossella Castagna, postdoctoral researcher at IBEC wins the ISOP2019 prize

Rossella Castagna a postdoctoral researcher in the Nanoprobes and Nanowitches group at IBEC was awared with the ISOP2019 prize last week 9th International Symposium on Photochromism held in Paris. This recognition comes from her contribution to the field of photochromism and for the results that were collectively obtained in their group in the field of photopharmacology.

Rossella presented the group results on photoswitchable drugs at the reference international meeting for photochromism, held every 3 years, where she was awarded with the conference prize. According to the organizing committee, such a prize rewards the most talented young researchers whose contribution is expected to notably impact the field of photochromism.

Three researchers from IBEC awarded with grants from “la Caixa” for their pioneering and high social impact research

José Antonio del Río, Pau Gorostiza, and Samuel Sánchez have been awarded in two of the “la Caixa” calls.

José Antonio del Río, principal investigator of the Molecular and Cellular Neurobiotechnology Group at IBEC, is one of the winners of the second edition of the call for applications in biomedicine and health. Del Río’s project focuses on analysing the molecular mechanisms involved in the genesis and propagation of tau protein in brain cells. This protein is linked with several neurodegenerative processes and is present in numerous diseases such as Alzheimer’s.

Pau Gorostiza, principal investigator of the Nanoprobes and Nanoswitches Group, also received an award at the second edition of the call for applications for research projects in biomedicine and health. In this case, for his project on degenerative eye conditions such as retinitis pigmentosa, which causes blindness due to the progressive degeneration of the cones and rods, which are the light sensitive cells.

Closer to a functional atlas of the brain

Scientists from the Institute for Bioengineering of Catalonia develop a technique that enables them to work out the specific function of a neuronal receptor according to its location in the brain. The study, published in PNAS, is based on the activation of photoswitchable drugs with micrometric precision and offers new opportunities in neurobiology.

Schizophrenia, depression, myasthenia… Many neurological diseases are due to the malfunctioning of a neuronal receptor. These proteins, also known as neuroreceptors, are responsible for sending and detecting neurotransmitters, chemical substances that allow communication between neurons.

ERC President visits IBEC

The President of the European Research Council, Jean-Pierre Bourguignon, visited last May 15th the Institute for Bioengineering of Catalonia (IBEC).

The event was inaugurated by IBEC’s Director, Josep Samitier, who presented an overview on the cutting-edge research carried out at the institute in the fields of bioengineering and nanomedicine.

Afterwards, ERC Grantees working at IBEC had the opportunity to explain the impact of ERC grants on their professional careers and established a dialogue with ERC President on the past, present and future of the European Research Council.

A new technique allows researchers to focus the action of drugs via infrared light

A scientific team led by IBEC and UAB manages to efficiently activate molecules located inside cell tissues using two-photon excitation of with infrared light lasers. The results of the study has been published in Nature Communications.

Having absolute control of the activity of a molecule in an organism. Deciding when, where and how a drug is activated. These are some of the goals expected to be reached with the so-called photoswitchable molecules, compounds that, in the presence of certain light waves, change their properties. Today, thanks to the results of a study led by the Institute for Bioengineering of Catalonia (IBEC) together with the Universitat Autònoma de Barcelona (UAB), the scientific community is one step closer to achieving this objective.

Proteins can transfer electrons at a distance

Collaborating IBEC groups have published a study in Nature Communications that reveals that electron transfer can take place while a protein is approaching its partner site, and not only when the proteins are engaged, as was previously thought.

The results open up a new way of thinking about how proteins interact, and can have implications in a better understanding of many processes – such as photosynthesis, respiration and detoxification – in which electron transfer plays an important role.

The relocation of an electron from one chemical entity to another – electron transfer (ET) – doesn’t happen passively: electrons are carried individually by redox proteins.

IBEC researchers uncover strategy to reduce chemotherapy side effects

Researchers at IBEC and IDIBELL have developed a light-regulated molecule that could improve chemotherapy treatments by controlling the activity of anticancer agents.

Chemotherapy – the use of cytotoxic agents to kill the rapidly proliferating cells in tumors – is one of our main tools in the fight against cancer. However, its effectiveness and the body’s tolerance of it is often dramatically limited: it can affect healthy areas rather than just the cancerous ones, which causes side effects.